Author Archives: Joana Carvalho

Persistent Hypoparathyroidism May Merit APS-1 Diagnosis

The presence of persistent hypoparathyroidism should prompt physicians to consider a possible diagnosis of autoimmune polyglandular syndrome type 1 (APS-1), a rare genetic disorder, even in the absence of other typical symptoms, according to a case report. The study, “Hypoparathyroidism as the single major component for decades…

TransCon PTH Phase 3 Clinical Trial Moving Forward

Ascendis Pharma anticipates it will announce top-line data from a new Phase 3 clinical trial of TransCon PTH, the company’s investigational hormone replacement therapy for hypoparathyroidism, before the end of the year, according to a recent company update. The study, called PaTHway (NCT04701203), seeks to assess the…

Inadequate Medical Care Still a Major Struggle in US, Survey Finds

People with hypoparathyroidism living in the U.S. still struggle to receive proper medical care, particularly during emergency room visits, according to findings of a survey conducted by the HypoPARAthyroidism Association (HPA). The results of the HPA’s “Voices of Hypopara” survey were released in support of World Hypoparathyroidism…

Takeda Issues U.S. Recall of Natpara Due to Risks from Packaging

Takeda has issued a U.S. recall of its prescription parathyroid hormone Natpara, due to the potential risk of small rubber fragments detaching from the products’ external protection cap with repeated use. The recall includes all doses of Natpara (human parathyroid hormone, or PTH) for injection — 25 mcg,…